. 2015 Jun 4;38(8):737–747. doi: 10.1007/s40264-015-0302-z

Table 2.

Overview of the numbers of prescriptions, the women to whom they were prescribed and their compliance rate for the first trimester and the entire pregnancy

Medication	A		B
Medication	Prx (n)	Maximum no. of prx per pregnancy	Women given a prx at least once (n)	Women with >1 prx (n)	%	Women who confirmed use of ≥1 prx (n)	Compliance rate (95% CI)
First trimester
All medicines together	314	19	129	75	58	117	0.91 (0.86–0.96)^b
Medicines for chronic diseases together	85	5	45	24	53	38	0.84 (0.74–0.95)^b
Antihypertensives, vasoprotectives, beta blocking agents, CCBs	8	3	^a	^a	^a	^a	^a
Corticosteroids, dermatological preparations	15	2	13	2	15	9	0.69 (0.42–0.87)^c
Medicines for obstructive airway diseases	21	5	10	6	60	9	0.90 (0.60–0.98)c
Medicines for short-term and occasional use together	113	6	70	24	34	60	0.86 (0.78–0.94)^b
Medicines for functional GI disorders and medicines for peptic ulcer and GORD	18	3	12	4	33	11	0.92 (0.65–0.99)^c
Dermatologicals exclusive anti-psoriatics and corticosteroids, dermatological preparations	27	4	20	4	20	18	0.90 (0.70–0.97)^c
Antifungals for dermatological use	7	1	^a	^a	^a	^a	^a
Emollients and protectives	8	3	^a	^a	^a	^a	^a
Antibacterials for systemic use	31	2	28	3	10	23	0.82 (0.64–0.92)^c
Anxiolytics, hypnotics and sedatives	3	1	^a	^a	^a	^a	^a
Ear, eye, nose and throat preparations	17	2	13	4	30	9	0.69 (0.42–0.87)^c
Medicines for pregnancy-related symptoms	116	8	60	27	45	55	0.92 (0.82–0.96)^c
Antacids	1	1	^a	^a	^a	^a	^a
Anti-emetics	47	7	26	9	35	21	0.81 (0.62–0.91)^c
Laxatives	11	2	^a	^a	^a	^a	^a
Multivitamins containing folic acid or folic acid and its derivatives	19	3	14	4	29	14	1.00 (0.78–1.00)^c
Iron preparations	11	3	^a	^a	^a	^a	^a
Gynecological anti-infectives and antiseptics	27	2	23	4	17	23	1.00 (0.86–1.00)^c
Entire pregnancy
All medicines together	817	29	202	140	69	193	0.96 (0.93–0.98)^b
Medicines for chronic diseases together	212	10	77	49	64	71	0.92 (0.86–0.98)^b
Antihypertensives, vasoprotectives, beta-blocking agents, CCBs	45	10	20	10	50	20	1.00 (0.84–1.00)^c
Corticosteroids, dermatological preparations	43	9	24	7	29	18	0.75 (0.58–0.92)^b
Medicines for obstructive airway diseases	47	7	17	9	53	16	0.94 (0.73–0.99)^c
Medicines for short-term and occasional use together	317	12	128	74	58	115	0.90 (0.85–0.95)^b
Medicines for functional GI disorders and medicines for peptic ulcer and GORD	37	6	17	7	41	16	0.94 (0.73–0.99)^c
Dermatologicals exclusive anti-psoriatics and corticosteroids, dermatological preparations	65	5	38	14	37	34	0.89 (0.76–0.96)^c
Antifungals for dermatological use	21	3	16	3	19	14	0.88 (0.64–0.97)^c
Emollients and protectives	28	4	14	7	50	13	0.93 (0.69–0.99)^c
Antibacterials for systemic use	107	6	67	24	36	57	0.85 (0.77–0.94)^b
Anxiolytics, hypnotics and sedatives	13	2	11	2	18	8	0.73 (0.43–0.90)^c
Ear, eye, nose, and throat preparations	54	6	31	14	45	26	0.84 (0.67–0.93)^c
Medicines for pregnancy-related symptoms	288	19	112	65	58	106	0.95 (0.90–0.99)^b
Antacids	25	4	14	5	36	13	0.93 (0.69–0.99)^c
Anti-emetics	71	19	30	11	37	24	0.80 (0.66–0.94)^b
Laxatives	33	4	22	7	32	18	0.82 (0.61–0.93)^c
Multivitamins containing folic acid or folic acid and its derivatives	34	4	16	8	50	16	1.00 (0.81–1.00)^c
Iron preparations	42	4	22	11	50	19	0.86 (0.67–0.95)^c
Gynecological anti-infectives and antiseptics	83	5	52	22	42	51	0.98 (0.90–1.00)^c

Columns marked ‘A’ focus on the prescriptions and the distribution; columns marked ‘B’ focus on the number of women to whom prescriptions were given, whether they receive one or more prescriptions, and their compliance rates

CCBs calcium channel blockers, CI confidence interval, GI gastrointestinal, GORD gastroesophageal reflux disease, prx prescription

^a<10 women were prescribed in this subgroup

^bWald method was applied

^cWilson method was applied